CONEXXENCE Q Code: Q5158

Conexxence is a medication aligned to the HCPCS Q Code: Q5158 for billing, pricing, and reimbursement purposes in the United States. Classified under Osteoporosis, it is administered via the subcutaneous route and manufactured by Fresenius Kabi.

According to CMS Drug Use Information: Denosumab is used to treat bone loss (osteoporosis) in people who have a high risk of getting fractures. Osteoporosis causes bones to become thinner and break more easily. Your chance of developing osteoporosis increases after menopause (in women), as you age, if someone in your family has osteoporosis, or if you take certain medications (such as prednisone) for long periods. This medication works by slowing bone loss to help maintain strong bones and reduce the risk of broken bones (fractures). Denosumab belongs to a class of drugs called monoclonal antibodies. It prevents certain cells in the body (osteoclasts) from breaking down bone. This monograph is about the following denosumab products: denosumab, denosumab-bbdz, denosumab-bmwo, denosumab-bnht, denosumab-desu, denosumab-dssb, denosumab-kyqq, denosumab-nxxp, and denosumab-qbde.

Disclaimer: This is a summary and does not contain all possible information about this product. For complete information about this product or your specific health needs, ask your healthcare professional.